









Markets
/
Stocks
/
nasdaq-srpt
/

Sarepta Therapeutics Inc

SRPT

View Detailed Chart

16.750USD

-0.350-2.05%

Close 08/05, 16:00（ET）Quotes delayed by 15 min

1.65BMarket Cap

LossP/E TTM



Sarepta Therapeutics Inc

16.750

-0.350-2.05%

Overview Company Financials

Financials

Intraday

30m

Today

-2.05%

5 Days

+5.81%

1 Month

-8.17%

6 Months

-85.93%

Year to Date

-86.22%

1 Year

-88.09%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 30 analysts

HOLD

Current Rating

30.960

Target Price

81.05%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

173

Total

Median

Average

Company name

Ratings

Analysts

Sarepta Therapeutics Inc

SRPT

Biogen Inc

BIIB

Vertex Pharmaceuticals Inc

VRTX

Alnylam Pharmaceuticals Inc

ALNY

Amgen Inc

AMGN

Gilead Sciences Inc

GILD

...

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Neutral

Sell(5)

Neutral(5)

Buy(3)

Indicators

Sell(2)

Neutral(5)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

1.776

Neutral

RSI(14)

45.182

Neutral

STOCH(KDJ)(9,3,3)

70.119

Neutral

ATR(14)

2.803

Low Volatility

CCI(14)

48.329

Neutral

Williams %R

49.096

Neutral

TRIX(12,20)

-1.616

Sell

StochRSI(14)

75.216

Sell

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

16.586

Buy

MA10

15.075

Buy

MA20

16.308

Buy

MA50

23.698

Sell

MA100

40.886

Sell

MA200

79.434

Sell

News

Sarepta Surges Over 14% as FDA Lifts Shipping Ban; Wall Street Anticipates Doubling in Stock Price

TradingKey - Sarepta Therapeutics (SRPT.US) announced on Monday, July 28, that it has resumed shipments of its gene therapy Elevidys in the U.S., following an authorization from the U.S. Food and Drug Administration (FDA). The company's stock spiked over 20% on Tuesday, closing up 14.21% at $15.83,

TradingKeyWed, Jul 30

Sarepta down after pausing Elevidys shipments in US

Shares of Sarepta Therapeutics SRPT.O down 1.7% at $13.10; they fell nearly 8% in premarket trading

ReutersTue, Jul 22

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. It has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes approximately 40 programs at various stages of discovery, pre-clinical and clinical development.

Ticker SymbolSRPT

CompanySarepta Therapeutics Inc

CEOMr. Douglas S. (Doug) Ingram, Esq., J.D.

Websitehttps://www.sarepta.com/